Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Age 20-55 years.~* Naïve or previously hepatitis B-vaccinated males or females.~* Normal and healthy as determined by medical history, physical exam, vital signs and clinical laboratory tests~* Subject must meet all required/recommended subject suitability criteria that pertain to normal source plasma donors with the following exception:~* Subjects who previously tested positive for HBsAg may be accepted into the anti- HBs program provided they now test negative and meet all other normal donor suitability criteria.~* Written informed consent.~Exclusion Criteria:~* Subjects who have received a hepatitis B vaccination in the previous six months.~* History of hypersensitivity to yeast or any components of the Engerix-B® vaccine~* History of hypersensitivity to any hepatitis B-containing vaccine.~* Use of any investigational product within the past 30 days or during the course of the study.~* Use of steroids or immunosuppressives during the study period.~* Received immunosuppressive therapy (including systemic steroids) within 30 days before study entry~* Subjects who have received cytotoxic therapy (in the previous 5 years prior to study entry)~* Received parenteral immune globulin products or blood products within 3 months before study entry with the following exceptions:~* RhoGAM (or equivalent anti-D immune globulin) within 6 weeks before study entry;~* Pertussis immune globulin: no exclusion~* Received parenteral immune globulin products or blood products (within 3 months before study entry)~* Past, present, or suspected IV drug use~* Positive HIV, HBV\* or HCV test result (\*except as described above in Inclusion Criteria)~* Autoimmune disease (such as, but not limited to demyelinating disease)~* Subjects with cancer, heart disease (including hospitalization for myocardial infarction, arrhythmia, syncope, congestive heart failure), uncontrolled hypertension, uncontrolled insulin-dependent diabetes mellitus, seizures, kidney disease~* Severely or morbidly obese, or higher obesity classification, which corresponds to BMI of 35 or higher~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Schedule 1- Standard dose primary vaccination series (Type: ACTIVE_COMPARATOR): Schedule 1 subjects received 20 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
- Schedule 2 - High dose primary vaccination series (Type: EXPERIMENTAL): Schedule 1 subjects received 40 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 60, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy